WillItSurvive
Medical technology and health companies · United States

Noom

noom.com ↗

App that sells weight-loss coaching plus resold GLP-1 prescriptions.

Protection under test
Assessed 22 July 2026 · Evidence as of 22 July 2026
Something worth protecting exists and is being tested right now.
On the recordSince 22 July 2026 · Checkable from H2 2026 · Every call on the record Checkpoint: Novo Nordisk v. Eli Lilly litigation ruling, which could reset GLP-1 marketing and supply rules
The call

Noom now runs on resold GLP-1 drugs and health-plan contracts rather than its old coaching app, while drugmakers and AI chatbots both close in from opposite sides.

Noom is a health company that combines human coaching with prescription weight-loss drugs to help people lose weight. The problem is that the drugs themselves (made by companies like Eli Lilly and Novo Nordisk) now do most of the work, and those drugmakers are selling directly to customers instead of going through middlemen like Noom, which cuts into Noom's profits. At the same time, competitors like WeightWatches and Ro offer the same coaching-plus-drug package, and basic AI chatbots can now do the coaching part for almost nothing, so there is nothing that makes Noom special or hard to replace. The one thing that could change this would be if Noom proves it can keep customers longer and get better results than others, or if it gets bought by a much bigger company that can use it as one piece of a larger business.

Why
01
AI pressure: Generic AI chat coaches (ChatGPT-style bots). Noom already swapped human coaches for AI chat, so any chatbot maker can copy that same psychology script for free. Could AI do the core job? Yes, likely.
02
Bigger players: Eli Lilly (LillyDirect) and Novo Nordisk (Wegovy/Ozempic). Lilly and Novo now ship Zepbound and Wegovy straight to patients, cutting resellers like Noom out of the drug margin. Could a giant copy it? Yes, easily.
03
What protects it. Signed health-plan and employer contracts (Highmark, Collective Health) plus its own 46-state compounding pharmacy give it distribution rivals must rebuild from scratch.
What would change this call
LillyDirect or Novo expand direct-to-consumer Zepbound/Wegovy shipping into Noom's markets. Drugmakers cutting out resellers like Noom would compress its Rx margin, its main growth engine.
FDA tightens rules on compounded GLP-1s as branded supply normalizes in 2026. Would threaten the Tailor Made Compounding acquisition's revenue thesis.
Noom announces a third layoff round or a marked-down sale/IPO within 6 months. Would confirm the core business hasn't stabilized despite GLP-1 revenue growth.
Key numbers
  • GLP-1 sales hit $100M run-rate in 4 months (2025-02)
  • Bought Tailor Made Compounding, 46 states (2026-04)
  • Highmark deal covers ~2M eligible members (2026)
Named risks
  • Core coaching product commoditized by generative AI chat, already partly automated internally. Severity: high
  • Drugmakers (Lilly, Novo) expanding direct-to-consumer channels compress Noom's Rx margin. Severity: high
  • FDA tightening on compounded GLP-1s as branded supply normalizes threatens newly acquired pharmacy business. Severity: high
  • Revenue figures across sources conflict by over 5x with no audited financials to reconcile. Severity: medium
  • Repeated 2025 layoffs signal core weight-loss business underperformance despite GLP-1 pivot. Severity: medium
Rivals, as read in July 2026
RivalDirectionEvidence
WeightWatcherslosing to55+ year brand with own GLP-1 Clinic and generally cheaper monthly pricing as of Jan 2026
Eli Lilly (LillyDirect)losing toDirect-to-consumer Zepbound shipping disintermediates resellers like Noom despite March 2025 integration
Novo NordiskcontestingControls Wegovy/Ozempic supply; litigating against Lilly as of July 21, 2026, reshaping GLP-1 ecosystem Noom depends on
RocontestingAlso sells oral GLP-1 alternative Foundayo as of April 2026 (vendor-claimed)
Found and CalibratecontestingOffer near-identical coaching plus GLP-1 prescription bundles as of 2026
Questions people ask
Is Noom profitable in 2026?
No audited financials exist since Noom is private. Revenue estimates conflict wildly, from $182M to over $1B depending on source, and Noom has cut staff twice in 2025 citing losses in its core weight loss business, suggesting the core app is not covering costs on its own.
Could AI replace Noom's coaching product?
Largely yes for the psychology layer. Noom's own site already advertises AI plus human coaching chat, and its coaching headcount has fallen from over 3,000 coaches historically to roughly 700 to 1,200 total employees by mid 2026, showing AI substitution already underway inside the company itself.
Who is Noom's biggest competitor?
WeightWatchers is the closest incumbent threat, with a 55 plus year brand, its own GLP-1 Clinic, and generally cheaper monthly pricing as of January 2026. Ro, Found, and Calibrate also offer near identical coaching plus GLP-1 prescription bundles that compete directly with Noom Med.
Who owns Noom?
Noom is privately held and venture backed, not publicly traded. Its May 2021 Series F was led by Silver Lake with Oak HC/FT, Novo Holdings, Temasek, Sequoia Capital, RRE, and Samsung Ventures, reportedly valuing the company near $3.7B at that time.
Does Noom sell GLP-1 weight loss drugs?
Yes. Noom Med offers prescription access to branded drugs like Wegovy and Zepbound plus compounded semaglutide, and disclosed in February 2025 that its GLP-1 and generic pill programs reached about a $100M revenue run-rate within four months of a September 2024 launch, per Noom's own disclosure.
Is Noom planning an IPO in 2026?
No confirmed filing exists. Noom explored an IPO around a 10B valuation in 2022 per Bloomberg reporting, but shelved it amid layoffs. As of July 20, 2026, Noom is absent from active IPO pipeline trackers, meaning any listing would be an unexpected event, not a scheduled one.
Timeline
  • 2026-07-21Novo Nordisk sues Eli Lilly over GLP-1 advertising claims, reshaping drug marketing landscape Noom depends on.
  • 2026-07-01Medicare GLP-1 Bridge program launches with $50 copay pilot, expanding potential addressable market for Noom Med.
  • 2026-05-05Noom names Charles Duhigg advisor and releases Psychosocial GLP-1 Report on habit formation.
  • 2026-04-01Noom acquires Tailor Made Compounding, a licensed 503A pharmacy operating in 46 states.
  • 2025-05Second 2025 layoff round cuts coaches and customer service staff amid core business losses.
  • 2025-03-31Noom integrates with Eli Lilly's LillyDirect pharmacy for Zepbound vial access.
  • 2025-02-04Noom cuts coaching and staff as GLP-1 strategy fails to offset core weight-loss losses.
  • 2022-02Noom settles $62M class action over deceptive auto-renewal billing.
  • 2022April and October layoffs cut about 500 coaches amid shelved IPO plans.
  • 2021-05Noom raises $540M Series F led by Silver Lake at roughly $3.7B valuation.
Revision history
22 July 2026
First assessed. Protection under test. The text above is fixed as of this date and is not edited afterwards.
In the same band
23andMeAngelalign TechnologySharecare
More in Medical technology and health companies →
Sources